Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach